Research ArticleNeurosciencePublic Health Open Access | 10.1172/jci.insight.189732

Valentina Vozella,1 Vittoria Borgonetti,1 Bryan Cruz,1 Celsey M. St. Onge,1 Ryan Bullard,1 Roman Vlkolinsky,1 Diego Gomez Ceballos,1 Angela R. Ozburn,2 Amanda J. Roberts,3 Roberto Ciccocioppo,4 Michal Bajo,1 and Marisa Roberto1

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Vozella, V. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Borgonetti, V. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Cruz, B. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Onge, C. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Bullard, R. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Vlkolinsky, R. in: JCI | PubMed | Google Scholar |

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Ceballos, D. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Ozburn, A. in: JCI | PubMed | Google Scholar |

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Roberts, A. in: JCI | PubMed | Google Scholar |

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Ciccocioppo, R. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Bajo, M. in: JCI | PubMed | Google Scholar

1Department of Translational Medicine, Scripps Research Institute, La Jolla, California, USA.

2Department of Behavioral Neuroscience at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon, USA.

3Animal Models Core Facility, Scripps Research, La Jolla, California, USA.

4Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.

Address correspondence to: Marisa Roberto, Ph.D., Department of Translational Medicine, Scripps Research; 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Email: mroberto@scripps.edu.

Authorship note: VV, VB, and BC contributed equally to this work.

Find articles by Roberto, M. in: JCI | PubMed | Google Scholar |

Authorship note: VV, VB, and BC contributed equally to this work.

Published April 22, 2025 - More info

Published in Volume 10, Issue 8 on April 22, 2025
JCI Insight. 2025;10(8):e189732. https://doi.org/10.1172/jci.insight.189732.
© 2025 Vozella et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Published April 22, 2025 - Version history
Received: December 2, 2024; Accepted: March 7, 2025 View PDF Abstract

The FDA-approved phosphodiesterase type 4 (PDE4) inhibitor, apremilast, has been recently investigated as a pharmacotherapy for alcohol use disorder (AUD) with promising efficacy in rodent models and humans. However, apremilast’s effects on mechanical allodynia associated with AUD as well as distinct responses of this drug between males and females are understudied. The present study examined the behavioral and electrophysiological effects of apremilast in Marchigian Sardinian alcohol-preferring (msP) rats and their Wistar counterparts. We used a 2–bottle choice (2-BC) alcohol drinking procedure and tested mechanical sensitivity across our drinking regimen. Spontaneous inhibitory GABA-mediated postsynaptic currents from the central nucleus of the amygdala (CeA) following apremilast application were tested in a subset of rats using ex vivo electrophysiology. Transcript levels for Pde4a or -4b subtypes were assessed for their modulation by alcohol. Apremilast reduced alcohol drinking in both strains of rats. Apremilast reduced mechanical allodynia immediately after drinking, persisting into early and late abstinence. Apremilast increased GABAergic transmission in CeA slices of alcohol-exposed Wistars but not msP rats, suggesting neuroadaptations in msPs by excessive drinking and mechanical allodynia. Pde4 subtype transcript levels were increased in CeA by alcohol. These results suggest that apremilast alleviates co-occurring excessive drinking and pain sensitivity, and they further confirm PDE4’s role in pain-associated AUD.

Introduction

Alcohol use disorder (AUD) is a major global health and economic problem (1–3). Stress and anxiety are major factors that promote excessive alcohol consumption, as individuals may self-medicate to alleviate negative emotional states associated with these conditions (4, 5). As a result, AUD has a high comorbidity with depression, anxiety, and pain (6, 7). Furthermore, women and men experience AUD at different rates and present distinct sensitivity as well as putatively different physiological responses to anxiety and pain disorders (8–11). This poses etiological challenges for the treatment of AUD and necessitates the examination of distinct responsivity of pharmacotherapies between male and female patients. Furthermore, the neural mechanisms that mediate AUD and alcohol-related pain need additional examination to improve comprehensive clinical interventions.

Phosphodiesterase type 4 (PDE4) has recently been investigated as a target implicated in motivated behaviors for alcohol use (12–16). PDE4 is a class of enzymes responsible for degrading cyclic adenosine monophosphate (cAMP), a second messenger that controls the inflammatory cascade, and exists in 4 different subtypes (i.e., PDE4A/B/C/D) (17). PDE4 is predominately found in immune cells but is also abundantly expressed in the brain (15–17). A link between PDE4 and AUD was demonstrated in human genome-wide association studies (18, 19). Administration of apremilast, a nonselective PDE4 inhibitor that is FDA approved for the treatment of psoriasis and psoriatic arthritis, has shown efficacy in reducing alcohol intake in both human and rodent models (12, 20, 21). Apremilast decreases binge-like drinking and self-administration progressive ratio breakpoints in mice bred for alcohol intoxication (12). Apremilast also decreased stress- and dependence-induced alcohol escalation in mice (12). Lastly, apremilast reduced the action potential threshold of dopamine D1-type, but not D2-type, containing medium spiny neurons (MSNs) in the nucleus accumbens (NAc) (12). Because AUD is often comorbid with stress, anxiety, and/or pain, the role of PDE4 inhibition in brain regions more closely associated with these behaviors needs to be further explored.

The central nucleus of the amygdala (CeA) is a critical region involved in the behavioral output of alcohol addiction, stress, anxiety, and pain processing (22–24). The CeA also exerts sex-dependent modulation of alcohol drinking and pain (25–27). Specifically, the CeA modulates hyperalgesia, recruits pain-associated pathways, and promotes age- and sex-related differences in animal models of pain (27–30). Indeed, several preclinical studies have demonstrated that excessive alcohol intake predicts the development of mechanical allodynia (31–34). Mechanical allodynia is a hypersensitivity state that is defined as a painful sensation caused by innocuous stimuli (35). The neuronal networks of the CeA are mainly composed of inhibitory γ-aminobutyric acid (GABA) neurons (GABAergic neurons), and following stress and/or alcohol dependence, neuroadaptations occur via increases in GABAergic transmission (22, 23). However, the effect of PDE4 inhibition by apremilast in the CeA GABAergic system in models of co-occurring alcohol drinking and mechanical allodynia has not been studied yet.

The genetically selected Marchigian Sardinian alcohol-preferring (msP) rats are well characterized for their high alcohol intake, anxiety, and fear behavior (36, 37). Recently, we reported persistent pain in msP rats compared with their Wistar background counterparts, validating increased sensitivity to pain in this rat line (24). Thus, the present study examined the behavioral effects of apremilast on alcohol drinking and mechanical sensitivity (defined as allodynia) in msP rats versus their Wistar counterparts. We hypothesized that chronic alcohol would promote greater development in mechanical allodynia in msPs versus Wistars based on prior work, and that apremilast would block drinking and alcohol-related allodynia in a strain-dependent manner (24). Previous work showed that alcohol drinking alters brain Pde4a and -4b gene expression (12, 38, 39). Thus, we examined gene expression of Pde4a and -4b in the CeA and NAc and the acute effects of apremilast on CeA GABAergic synaptic transmission using electrophysiology, and we hypothesized that genetic and physiological disruptions of PDE4 would also occur in a strain-dependent manner (40, 41). Lastly, we included male and female groups across strains and drugs to understand sex differences produced by apremilast across our multidisciplinary study.

Results

Apremilast decreases voluntary 2–bottle choice (2-BC) alcohol drinking. The regimen for apremilast administration on alcohol drinking and dose groups was included in our experimental timeline (Figure 1, A and B). Apremilast significantly reduced alcohol intake for males and females of both strains of rats (Figure 2, A, B, E, and F). However, apremilast only reduced alcohol preference among Wistar females (Figure 2D) and msP males (Figure 2G). Apremilast did not significantly alter alcohol preference for Wistar males (Figure 2C) or msP females (Figure 2H). No differences in water intake for males or females of either strain of rats were observed (Supplemental Figure 1, A–D; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.189732DS1).

Figure 1

Timeline of apremilast testing on 2-BC alcohol drinking, mechanical allodynia, gene expression, and central amygdala (CeA) electrophysiology assessments. (A and B) Experimental approach (A) and design of apremilast dose regimen (B) on 2–bottle choice (BC) and von Frey testing across sex and strain. Rats first received 2 weeks of 10% alcohol for 24 hours/day. Starting on week 3, access to alcohol was reduced to 2 hours/day. During week 3–5, apremilast injections (0, 10, and 20 mg/kg; i.p.) was given in 3 cycles separated one week apart in a Latin square design. CeA electrophysiological recordings or isolation for PCR occurred on week 7, while recordings continued through week 8. A subset of rats were tested during late abstinence and received apremilast on week 9. All rats received apremilast injections 1 hour prior to testing on 2-BC, equivalent to 3 hours before von Frey testing on groups examined immediately after alcohol.

Figure 2

Apremilast decreases voluntary 2–bottle choice (2-BC) alcohol drinking across strain and sex. (A–H) Effects of apremilast (10 or 20 mg/kg) in the 2-BC drinking procedure (10% v/v alcohol) in Wistar (A–D) and msP (E–H) rats (n = 8–17 rats per group). (A) Wistar male alcohol intake, F2,33 = 3.61, P = 0.03. (B) Wistar female alcohol intake, F2,50 = 15.58, P < 0.0001. (C) Wistar male alcohol preference, F2,33 = 0.44, P = 0.64. (D) Wistar female alcohol preference: F2,50 = 6.74, P = 0.002. (E) msP male alcohol intake, F2,27 = 4.81, P = 0.02. (F) msP female alcohol intake, F2,21 = 4.05, P = 0.032. (G) msP male alcohol preference, F2,27 = 4.44, P = 0.020. (H) msP female alcohol preference, F2,21 = 1.29, P = 0.29. Results are expressed as mean ± SEM and analyzed as 1-way ANOVA followed by Dunnett’s multiple-comparison post hoc test. Significant difference relative to vehicle controls is denoted by *P < 0.05, **P < 0.01, *** P < 0.001, and ****P < 0.0001.

Apremilast decreases mechanical allodynia across strain and sex immediately after alcohol exposure and into early abstinence. Both male and female msP rats (Supplemental Figure 2, E and F) displayed increased mechanical sensitivity after alcohol consumption and during abstinence as compared with baseline, respectively. No differences were found between baseline across sexes for each strain (Supplemental Figure 2, A and D) or Wistar groups (Supplemental Figure 2, B and C).

To examine the effect of apremilast (0, 10, or 20 mg/kg; i.p.) on mechanical allodynia, von Frey testing was performed immediately after the 2-hour 2-BC drinking (3 hours after apremilast or vehicle injection) as well as in early abstinence (24 hours after injection). Immediately after alcohol drinking, apremilast (20 mg/kg) significantly reduced the alcohol-induced mechanical allodynia in female Wistars (Figure 3B) as well as male msPs (Figure 3E), but not in male Wistars or female msPs (Figure 3, A and F), when compared with vehicle-treated controls. This effect persisted in early abstinence 24 hours after alcohol removal (Figure 3, D, G, and H). There was no effect observed at the 10 mg/kg dose in Wistar or msP rats of either sex (Figure 3, A, B, E, and F). No effects were observed in Wistar males in early abstinence (Figure 3C).

Figure 3

Apremilast decreases mechanical allodynia across strain and sex immediately after alcohol exposure and into early abstinence. (A–H) Effects of apremilast (10 or 20 mg/kg) on mechanical allodynia tested immediately after alcohol exposure (3 hours after injection, directly after 2-BC: left panel; 3–5 weeks into 2-BC) as well as during early abstinence (24 hours after injection: right panel; 5 weeks into 2-BC 24 hours after the last sessions) in Wistar (A–D) and msP (E–H) rats (n = 8–18 rats per group). (A) Wistar male mechanical threshold directly following 2-BC. Treatment F1.918,21.10 = 1.17, P = 0.32. Individual F11,22 = 1.58, P = 0.17. (B) Wistar female mechanical threshold directly following 2-BC. Treatment F1.988,32.80=7.99, P = 0.001. (C) Wistar male mechanical threshold in early abstinence; median (Mdn) = 0.0, Wilcoxon statistic (W) = 0.0, P > 0.000. (D) Wistar female mechanical threshold in early abstinence, Mdn = 16.0, W = 122.0, P = 0.002. (E) msP male mechanical threshold directly following 2-BC. Treatment F1.27,11.40 = 5.0, P = 0.04. (F) msP female mechanical threshold directly following 2-BC. Treatment F1.70,11.93 = 3.68, P = 0.06. (G) msP male mechanical threshold in early abstinence; Mdn = 11.0, W = 21.0, P = 0.03. (H) msP female mechanical threshold in early abstinence; Mdn = 16.0, W = 28.0, P = 0.01. Results are expressed as mean ± SEM and analyzed as a RM 1-way ANOVA or mixed-effects analysis as appropriate with Geisser-Greenhouse correction (A, B, E, F) followed by Dunnett’s multiple-comparison post hoc test and paired or unpaired t test (C, D, G, H). Significant difference relative to vehicle controls is denoted by *P < 0.05 and **P < 0.01.

Apremilast reduces mechanical allodynia into protracted alcohol abstinence in female but not male msPs. To evaluate apremilast’s effect on mechanical allodynia during protracted alcohol abstinence, apremilast (20 mg/kg) was administered 4 weeks after the last alcohol-drinking session only in msP rats (as they exhibited mechanical allodynia during abstinence; Supplemental Figure 2, E and F). Apremilast (20 mg/kg) reduced mechanical allodynia during protracted alcohol abstinence when compared with the vehicle-treated group in female but not male msP rats (Figure 4, A and B).

Figure 4

Apremilast reduces mechanical allodynia into protracted alcohol abstinence in female but not male msPs. Effect of apremilast (20 mg/kg) on mechanical allodynia in msP rats tested 4 weeks from the last 2-BC session (week 9; n = 6–10 rats per group). (A) msP male time course in mechanical threshold. Time, F2,18=3.64, P = 0.04. Treatment, F1,9=10.48, P = 0.01. Time × Treatment, F2,18=1.87, P = 0.183. (B) msP female time course in mechanical threshold. Time, F2,10=2.70, P = 0.11. Treatment, F1,5=0.84, P = 0.40. Time × Treatment, F2,10=4.87, P = 0.03. Results are expressed as mean ± SEM and analyzed as a RM 2-way ANOVA followed by Tukey’s multiple comparisons post hoc test. Significant difference is denoted by *P < 0.05 and **P < 0.01.

Acute apremilast application increased spontaneous GABA transmission in ex vivo CeA slices of alcohol-exposed Wistar but not msP rats. We used a random subset of rats for electrophysiological study to determine (a) potential baseline differences in CeA inhibitory signaling and (b) the synaptic effects of acute apremilast. We performed whole-cell patch clamp recordings of pharmacological-isolated GABAA-mediated spontaneous inhibitory postsynaptic currents (sIPSC) in the medial subdivision of the CeA from male and female Wistar and msP rats that underwent 2-BC. Notably, CeA neurons from msP males displayed significantly larger basal sIPSC frequency (2.82 ± 0.7 Hz) compared with 2-BC Wistar males (1.2 ± 0.3 Hz; Figure 5, A and B), suggesting increased GABA release in the msP strain (41). Furthermore, female msPs display significantly decreased GABA release compared with female Wistar (Figure 6, A and B). To determine the modulatory role of apremilast on inhibitory synaptic transmission, we applied 1 μM apremilast for 12–15 minutes on CeA sIPSCs. We found that apremilast significantly increased the sIPSC frequency (by 17% ± 6%) in the CeA of male Wistars (Figure 5C), and rise (by 7%; Figure 6C) and decay times (by 11%; Figure 6C) in female Wistars, without affecting any of the parameters in msP rats. These data suggest that apremilast significantly increases presynaptic GABA release in male and postsynaptic GABAA function in female Wistars.

Figure 5

Acute apremilast application increased spontaneous GABA transmission in ex vivo CeA slices of male alcohol-exposed Wistar but not msP rats. (A) Representative baseline and during apremilast (1 μM) application of spontaneous inhibitory postsynaptic currents (sIPSC) in the CeA neurons from male Wistar and msP rats (n = 10–14 cells per group). All rats shared 2-BC alcohol access histories. (B) Baseline sIPSC frequency: t23 = 2.30, P = 0.03; amplitude: t23 = 0.07, P = 0.94; rise time: t23 = 2.21, P = 0.03; and decay time: t23 = 0.88, P = 0.38. (C) Effect of apremilast on sIPSC properties as compared with baseline frequencies: Wistar male, t10= 2.44, P = 0.03; all others not significant (ns) for amplitudes, rise time, and decay time. Results are expressed as mean ± SEM and analyzed as independent-sample t test for baselines or a 1-sample t test for apremilast effects. Significant difference is denoted by *P < 0.05 for apremilast effect, and #P < 0.05 strain effect.

Figure 6

Acute apremilast application increased spontaneous GABA transmission in ex vivo CeA slices of female alcohol-exposed Wistar but not msP rats. (A) Representative baseline and during apremilast (1 μM) application of spontaneous inhibitory postsynaptic currents (sIPSC) in the CeA neurons from female Wistar and msP rats (n = 8–15 cells per group). All rats shared 2-BC alcohol access histories. (B) Baseline sIPSC frequency: t23 = 2.57, P = 0.01; amplitude: t23 = 0.08, P = 0.93; rise time: t23 = 0.96, P = 0.34; and decay time: t23 = 1.20, P = 0.23. (C) Effect of apremilast on sIPSC properties as compared with baseline rise time: Wistar female, t14= 2.75, P = 0.01, and decay time, Wistar female, t14= 2.78, P = 0.01; all others not significant (ns) for frequency and amplitude. Results are expressed as mean ± SEM and analyzed as independent-sample t test for baselines or a 1-sample t test for apremilast effects. Significant difference is denoted by *P < 0.05 for apremilast effect and #P < 0.05 strain effect.

Chronic alcohol drinking increases CeA Pde4a and -4b transcript levels in a sex and strain dependent manner. Both CeA and NAc gene expression of Pde4 subtypes a and b were assessed in subsets of naive and alcohol-exposed Wistar and msP rats. In the CeA, chronic alcohol exposure significantly increased Pde4a transcript levels in male Wistar and msP rats (Figure 7, A and E), but no differences were observed in females of either strain (Figure 7, B and F). Chronic alcohol drinking also significantly increased CeA Pde4b transcript levels in both male and female Wistar and msP rats (Figure 7, C, D, G, and H).

Figure 7

CeA Pde4a and -4b transcript levels are increased by chronic alcohol exposure across strain and sex. (A–H) Effects of chronic alcohol exposure (7 weeks) on CeA Pde4a (left panels) and Pde4b (right panels) transcript levels in Wistar (A–D) and msP rats (E–H) (n = 5–6 rats per group). (A) CeA Pde4a male Wistar, t10 = 2.28, P = 0.029. (B) CeA Pde4a female Wistar, t10 = 1.39, P = 0.09. (C) CeA Pde4b male Wistar, t10= 3.68, P = 0.004. (D) CeA Pde4b female Wistar, t10 = 2.53, P = 0.02. (E) CeA Pde4a male msP, t10 = 2.20, P = 0.02. (F) CeA Pde4a female msP, t10 = 1.23, P = 0.12. (G) CeA Pde4b male msP, t10= 2.73, P = 0.01. (H) CeA Pde4b female msP, t10 = 2.51, P = 0.01. All results are shown as mean ± SEM as well as individual values and analyzed as unpaired t tests. Significant difference relative to naive controls is denoted by *P < 0.05 and **P < 0.01.

The same group of rats and genes were analyzed in the NAc. For Pde4a, chronic alcohol drinking significantly increased NAc Pde4a transcript levels in msP males (Supplemental Figure 3E) but not Wistar males (Supplemental Figure 3A). In contrast, alcohol decreased NAc Pde4a in females across both strains of rats (Supplemental Figure 3, B and F). Lastly, alcohol increased NAc Pde4b in Wistar male rats (Supplemental Figure 3C) but not the other strain or sex groups (Supplemental Figure 3 D, G, and H).

Discussion

The present study investigated the effect of the PDE4 inhibitor apremilast on co-occurring alcohol drinking and mechanical allodynia in genetically selected msP rats and their Wistar counterparts. Based on prior work (12, 21), we hypothesized that PDE4 inhibition with apremilast would decrease alcohol drinking and alcohol-induced mechanical allodynia in rats. Apremilast decreased alcohol drinking in both strains and sexes, consistent with previous work (42). Apremilast also decreased mechanical allodynia during alcohol exposure, as well as during early (24 hours) and protracted (4 weeks) abstinence across strains and sex (but not in male Wistars). Our electrophysiological data show significant strain- and sex-dependent changes in baseline GABAergic transmission. Acute apremilast application increased presynaptic CeA GABA (sIPSC frequency) release, and GABAA receptor function (i.e., sIPSC rise and decay) in male and female Wistar rats, respectively — an effect that was absent in msP groups. CeA Pde4a and Pde4b transcript levels were increased by alcohol across groups of sex and strain, similar to prior work in the striatum of animal models of binge-like drinking (12, 13). Collectively, these findings support the role of PDE4 in alleviating co-occurring AUD and increased pain sensitivity in both sexes.

Males and females of both strains displayed decreased alcohol drinking after administration with apremilast. This finding is in line with recent published reports testing PDE4 inhibitors across multiple animal models of AUD and selectively bred mouse strains for high alcohol intake (13, 21, 42, 43). Our results show that rats (both sexes, 2 strains) display similar reduction profiles in drinking behavior with apremilast. Other studies have examined sex differences with different classes of PDE4 inhibitors. For example, the PDE4 inhibitor rolipram decreased alcohol drinking in male and female High Drinking in the Dark (HDID, lines 1 and 2) mice and the genetically Heterogeneous Stock/Northport (HS/Npt) mice (44). A nonselective PDE inhibitor, ibudilast, decreased alcohol relapse behavior in rodents and in both male and female patients (45, 46). Specific subtypes such as PDE4A or -B have the ability to promote different roles in drinking between sexes. Studies with selective PDE4B inhibitors report mixed results, where Chavez et al. showed reductions in drinking in 2 sub-strains of mice and Blednov et al. found no effect on alcohol intake in mice but observed decreased alcohol-related ataxia (47, 48). The Blednov et al. report showed that a PDE4D inhibitor subtype decreased drinking in both male and female mice (47). Future studies are needed to characterize the role of specific PDE4 subtypes across sex and strain and their underlying mechanisms that reduce drinking.

Our work expands previous observations made in msP rats, a genetic animal model of excessive alcohol drinking that cosegregates with hyperanxiety and depressive-like conditions (49, 50). To our knowledge, there are no reports examining the effect of apremilast on alcohol-associated mechanical allodynia. However, apremilast has been shown to decrease autoimmune disease–related pain states (51). In our study, apremilast reduced mechanical allodynia across multiple phases of alcohol drinking, including early and protracted abstinence in both sexes and strains (but no effect in Wistar males). Differences in the efficacy of apremilast to reduce allodynia between male and female Wistars might depend on variation in their propensity to develop allodynia. We recently observed a higher tendency of female Wistars (compared with male) to develop allodynia in the 2-BC model, suggesting differences in the magnitude of pain and sensitivity for reducing pain with apremilast (24). We also note that msP and Wistar rats spontaneously drink different amounts of alcohol (msP taking more), which may influence the effects of apremilast on mechanical allodynia associated with alcohol exposure. While this is the first report of the effects of apremilast on co-occurring alcohol drinking and mechanical allodynia, other PDE4 inhibitors have been tested for non-alcohol-related pain behavior. Rolipram decreases neuropathic pain by reversing mechanical hypersensitivity in a mouse model of peripheral nerve injury (52). Selective knockdown of Pde4b via intrathecal injections of siRNA blocks pain hypersensitivity in a rat model of L5 spinal nerve ligation (53). Our research group recently reported changes in the dorsal root ganglion (DRG) endocannabinoid system in msP rats that also experienced persistent mechanical allodynia into late abstinence (24). In addition, Megat et al. (52) found that rolipram acts on nonneuronal glial cells of the DRG and exerts antiallodynic action and reduced expression of proinflammatory target TNF-α, suggesting that modulation of PDE4 for pain sensitivity occurs at the DRG level (52).

When we evaluated CeA Pde4a and Pde4b transcript levels, we found a generalized increase in their expression following alcohol, as similarly found in the striatum of animal models of binge-like drinking (12, 13). Additionally, we observed that apremilast increases spontaneous CeA GABA transmission in Wistar rats but not in msP rats. The effects of apremilast have been reported in other interconnected limbic structures, including the NAc. For instance, apremilast administration activates both excitatory and inhibitory synaptic inputs to the NAc MSN, with increased excitability of D1- but not D2-expressing NAc MSNs (12). Site-specific intra-NAc administration of apremilast is sufficient to decrease binge-like alcohol drinking in mice selectively bred for alcohol intoxication (12), pointing to a possible locus for NAc PDE4 in modulating the behavioral effects of alcohol drinking. It is also recognized that the role of PDE4 may involve other structures including the periaqueductal gray (PAG) due to connections with CeA to influence drinking and hyperalgesia (54, 55). CeA-PAG projections mediate thermal hyperalgesia in alcohol-dependent rats, and alcohol dependence reduced inhibition of PAG neurons evoked from CeA inputs (55). Future studies are needed to functionally validate involvement of CeA PDE4, including other structures in co-occurring drinking and alcohol-relat